Literature DB >> 19798023

Are new agents needed to treat RA?

Peter E Lipsky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19798023     DOI： 10.1038/nrrheum.2009.197

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  2 in total

1.  Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.

Authors:  Diane van der Woude; Adam Young; Keeranur Jayakumar; Bart J Mertens; René E M Toes; Désirée van der Heijde; Tom W J Huizinga; Annette H M van der Helm-van Mil
Journal:  Arthritis Rheum       Date:  2009-08

2.  Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.

Authors:  E C Keystone; M C Genovese; L Klareskog; E C Hsia; S T Hall; P C Miranda; J Pazdur; S-C Bae; W Palmer; J Zrubek; M Wiekowski; S Visvanathan; Z Wu; M U Rahman
Journal:  Ann Rheum Dis       Date:  2008-12-09       Impact factor: 19.103
  2 in total
  2 in total

1.  Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients.

Authors:  Damini Jawaheer; Susan Messing; George Reed; Veena K Ranganath; Joel M Kremer; James S Louie; Dinesh Khanna; Jeffrey D Greenberg; Daniel E Furst
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-12       Impact factor: 4.794

2.  Etanercept ameliorates inflammation and pain in a novel mono-arthritic multi-flare model of streptococcal cell wall induced arthritis.

Authors:  Kalyan Chakravarthy; Robert Faltus; Gain Robinson; Raquel Sevilla; John Shin; Mark Zielstorff; Alan Byford; Erica Leccese; Michael J Caniga; SuChun Hseih; Shuli Zhang; Chi-Sung Chiu; Jie Zhang-Hoover; Lily Y Moy; Robbie L McLeod; Dana Stoffregen; Weisheng Zhang; Anwar Murtaza; Milenko Cicmil
Journal:  BMC Musculoskelet Disord       Date:  2014-12-04       Impact factor: 2.362
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.